
EMBO Member
María S. Soengas
EMBO 2022
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
Mechanisms and therapeutic targets in melanoma
Our group is interested in identifying progression biomarkers and therapeutic agents in melanoma, a highly metastatic disease. We combine histopathological studies in large patient datasets with functional analyses in animal models designed for gene discovery and pharmacological studies in vivo. We have discovered new melanoma drivers and mechanisms of immunoresistance, and have developed anticancer agents with derivatives now in clinical trials.
Keywords
Cancer / melanoma / metastasis / drug development / pharmacological screen